Cell metabolism · 2020
Metformin Is Associated with Higher Incidence of Acidosis, but Not Mortality, in Individuals with COVID-19 and Pre-existing Type 2 Diabetes.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Cheng Xu, Liu Ye-Mao, Li Haomiao, Zhang Xin, Lei Fang, Qin Juan-Juan, Chen Ze, Deng Ke-Qiong, Lin Lijin, Chen Ming-Ming, Song Xiaohui, Xia Meng, Huang Xuewei, Liu Weifang, Cai Jingjing, Zhang Xiao-Jing, Zhou Feng, Zhang Peng, Wang Yibin, Ma Xinliang, Xu Qingbo, Yang Juan, Ye Ping, Mao Weiming, Huang Xiaodong, Xia Jiahong, Zhang Bing-Hong, Guo Jiao, Zhu Lihua, Lu Zhibing, Yuan Yufeng, Wei Xiang, She Zhi-Gang, Ji Yan-Xiao, Li Hongliang
Аннотация
The safety and efficacy of anti-diabetic drugs are critical for maximizing the beneficial impacts of well-controlled blood glucose on the prognosis of individuals with COVID-19 and pre-existing type 2 diabetes (T2D). Metformin is the most commonly prescribed first-line medication for T2D, but its impact on the outcomes of individuals with COVID-19 and T2D remains to be clarified. Our current retrospective study in a cohort of 1,213 hospitalized individuals with COVID-19 and pre-existing T2D indicated that metformin use was significantly associated with a higher incidence of acidosis, particularly in cases with severe COVID-19, but not with 28-day COVID-19-related mortality. Furthermore, metformin use was significantly associated with reduced heart failure and inflammation. Our findings provide clinical evidence in support of continuing metformin treatment in individuals with COVID-19 and pre-existing T2D, but acidosis and kidney function should be carefully monitored in individuals with severe COVID-19.